Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Objective: To evaluate the effects of the glucagon-like peptide-1 receptor agonist lixisenatide on elevated liver blood tests in patients with type 2 diabetes. Design: Systematic review. Data sources: Electronic and manual searches were combined. Study selection: Randomised controlled trials (RCTs) on lixisenatide versus placebo or active comparators for type 2 diabetes were included. Participants: Individual patient data were retrieved to calculate outcomes for patients with elevated liver blood tests. Main outcome measures: Normalisation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Data synthesis: The results of included trials were combined in meta-analyses. Sequential, subgroup and regression analyses were performed to evaluate heterogeneity and bias. Results: We included 12 RCTs on lixisenatide versus placebo and 3 RCTs with the active comparators liraglutide, exenatide or sitagliptin. The mean treatment duration was 29 weeks. Lixisenatide increased the proportion of patients with normalisation of ALT (risk difference: 0.07; 95% CI 0.01 to 0.14; number needed to treat: 14 patients, p=0.042). The effect was not confirmed in sequential analysis. No effects of lixisenatide were identified on AST, alkaline phosphatase or bilirubin. No evidence of bias was identified. Mixed effect multilevel meta-regression analyses suggest that the benefit of lixisenatide on ALT was limited to patients who were overweight or obese. Conclusions: This review suggests that lixisenatide increases the proportion of obese or overweight patients with type 2 diabetes who achieve normalisation of ALT. Additional research is needed to determine if the findings translate to clinical outcome measures. Trial registration number: PROSPERO; CRD42013005779.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Post-hoc analyses on the effects of other GLP-1RA on liver enzymes showed a reduction in liver enzymes with lixisenatide [113] and exenatide [110,144,153].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [113]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Angelico, F., Burattin, M., Alessandri, C., Del Ben, M., & Lirussi, F. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005166.pub2 · Cited by 114
RetractedCochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Chapter 9: Analysing Data and Undertaking Meta-Analyses
Deeks, J. J., Higgins, J. P. T., & Altman, D. G. (2008) · Cited by 2,782
Analysing Data and Undertaking Meta‐Analyses
Deeks, J. J., Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch9 · Cited by 1,800
Szczepaniak, L. S., Nurenberg, P., Leonard, D., Browning, J. D., Reingold, J. S., Grundy, S., Hobbs, H. H., & Dobbins, R. L. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,562
The burden of liver disease in Europe: A review of available epidemiological data
Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D.-C., & Roudot-Thoraval, F. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.12.005 · Cited by 1,341
Bedogni, G., Miglioli, L., Masutti, F., Tiribelli, C., Marchesini, G., & Bellentani, S. (2005) · Hepatology · doi:10.1002/hep.20734 · Cited by 1,263
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., Day, C., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc06-2247 · Cited by 992
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Self-citationDing, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557
Gupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532
Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2454 · Cited by 288
Malottki, K., Barton, P., Tsourapas, A., Uthman, A., Liu, Z., Routh, K., Connock, M., Jobanputra, P., Moore, D., Fry-Smith, A., et al. (2011) · Health Technology Assessment · doi:10.3310/hta15140 · Cited by 287
Seino, Y., Min, K. W., Niemoeller, E., Takami, A., & on behalf of the EFC10887 GETGOAL‐L Asia Study Investigators (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01618.x · Cited by 255
Rosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253
Riddle, M. C., Forst, T., Aronson, R., Sauque-Reyna, L., Souhami, E., Silvestre, L., Ping, L., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2462 · Cited by 253
Seino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247
Stewart, G. B., Altman, D. G., Askie, L. M., Duley, L., Simmonds, M. C., & Stewart, L. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046042 · Cited by 232
Dormandy, J., Bhattacharya, M., & van Troostenburg de Bruyn, A.-R. (2009) · Drug Safety · doi:10.2165/00002018-200932030-00002 · Cited by 227
Bleeding Complications after Percutaneous Liver Biopsy
Terjung, B., Lemnitzer, I., Dumoulin, F. L., Effenberger, W., Brackmann, H. H., Sauerbruch, T., & Spengler, U. (2003) · Digestion · doi:10.1159/000071293 · Cited by 222 · cited 1×
“Biopsy-related complications including bleeding still occur in ultrasonically guided techniques.(10) 11 Treatment of NAFLD and NASH is important.”
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218
Kapitza, C., Forst, T., Coester, H. ‐., Poitiers, F., Ruus, P., & Hincelin‐Méry, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12076 · Cited by 191
Ahrén, B., Leguizamo Dimas, A., Miossec, P., Saubadu, S., & Aronson, R. (2013) · Diabetes Care · doi:10.2337/dc12-2006 · Cited by 172
Ratner, R. E., Rosenstock, J., Boka, G., & on behalf of the DRI6012 Study Investigators (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03020.x · Cited by 155
Lorenz, M., Pfeiffer, C., Steinsträßer, A., Becker, R. H. A., Rütten, H., Ruus, P., & Horowitz, M. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.04.001 · Cited by 149
Bolli, G. B., Munteanu, M., Dotsenko, S., Niemoeller, E., Boka, G., Wu, Y., & Hanefeld, M. (2014) · Diabetic Medicine · doi:10.1111/dme.12328 · Cited by 144
Pinget, M., Goldenberg, R., Niemoeller, E., Muehlen‐Bartmer, I., Guo, H., & Aronson, R. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12121 · Cited by 139
Lixisenatide for type 2 diabetes mellitus
Christensen, M., Knop, F. K., Vilsbøll, T., & Holst, J. J. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.562191 · Cited by 84
Self-citationOverview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease
Baršić, N., Lerotić, I., Smirčić-Duvnjak, L., Tomašić, V., & Duvnjak, M. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i30.3945 · Cited by 84 · cited 1×
“Elevation of alanine aminotransferase (ALT) is more common than aspartate aminotransferase (AST).(9) The gold standard for the assessment of patients with NAFLD is to perform a liver biopsy, but the procedure is associated with risks and potential sampling errors.”
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Shyangdan, D., Clar, C., Ghouri, N., Henderson, R., Gurung, T., Preiss, D., Sattar, N., Fraser, A., & Waugh, N. (2011) · Health Technology Assessment · doi:10.3310/hta15380 · Cited by 74 · cited 1×
“A subsequent health technology assessment on insulin sensitisers for NAFLD reached a similar conclusion.(13) However, pioglitazone is associated with a considerable risk of serious adverse events including cardiovascular disease and bladder cancer.”
Miller, M. H., Ferguson, M. A. J., & Dillon, J. F. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02451.x · Cited by 60 · cited 8×
“observational studies found that routinely available biochemical markers may be used in the assessment of NAFLD.(8) Elevation of alanine aminotransferase (ALT) is more common than aspartate aminotransferase (AST).”
InfluentialDíaz-Soto, G., de Luis, D. A., Conde, R., Izaola-Jáuregui, O., Ramos, C., & Romero, E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.01.019 · Cited by 56 · cited 1×
“insulin sensitivity and resistance most likely via their body weight -lowering effect.(16) In addition, GLP-1RAs may have a direct effect on hepatocytes reducing hepatic steatosis via glucagon-like peptide-1 receptors in the liver.”
Potential of incretin-based therapies for non-alcoholic fatty liver disease
Samson, S. L., & Bajaj, M. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.12.005 · Cited by 47 · cited 1×
“Experimental studies suggest that activation of GLP-1 receptors may prevent diabetes-related comorbidity including obesity and NASH,(38) and that GLP-1RAs may improve hepatic steatosis.(39) The beneficial effects of GLP-1RA include improved glycaemic control as well as beneficial effects on body weight, blood pressure…”
Ultrasound-guided percutaneous liver biopsy: indications, risks, and technique.
Copel, L., Sosna, J., Kruskal, J. B., & Kane, R. A. (2003) · PubMed · Cited by 36
Non-Invasive Diagnostic Tests for Non-Alcoholic Fatty Liver Disease
Estep, M., Birerdinc, A., & Younossi, Z. M. (2010) · Current Molecular Medicine · doi:10.2174/156652410790963321 · Cited by 30 · cited 1×
“Elevated transaminases are independent predictors of NAFLD although the sensitivity is low.(7) A large proportion of patients with type 2 diabetes and elevated transaminases have NAFLD or NASH.”
Lewis, J. D., Habel, L., Quesenberry, C., Mamtani, R., Peng, T., Bilker, W. B., Hedderson, M., Nessel, L., Vaughn, D. J., Strom, B. L., et al. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3619 · Cited by 27
Lixisenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Scott, L. J. (2013) · BioDrugs · doi:10.1007/s40259-013-0057-y · Cited by 26 · cited 1×
“and reduces body weight in patients with type 2 diabetes.(19) 20 There are no RCTs on lixisenatide for patients with NAFLD.”
Parkash, O., & Hamid, S. S. (2013) · PubMed · Cited by 24
Seino, Y., Yabe, D., Takami, A., Niemoeller, E., & Takagi, H. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.07.003 · Cited by 18
Treatment of non-alcoholic fatty liver disease: can we already face the epidemic?
Verbeek, J., Cassiman, D. M., Lannoo, M., Laleman, W., der Merwe, V., Verslype, C., Steenbergen, W. V., & Nevens, F. (2013) · PubMed · Cited by 16
Research works printed but not linked: 1
- Ratner RE, Hanefeld M, Shamanna P, et al. Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on sulfonylurea ± metformin (GetGoal-S). Diabetologia 2011;54:785.
Cited by
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.014 · Cited by 1,211
Non-alcoholic fatty liver disease and dyslipidemia: An update
Katsiki, N., Mikhailidis, D. P., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.05.003 · Cited by 564
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., & Targher, G. (2021) · Metabolites · doi:10.3390/metabo11020073 · Cited by 299
“To our knowledge, compared to recently published systematic review articles on this topic [20,36,40,41], this is the largest and most updated systematic review and meta-analysis of RCTs that used different GLP-1 RAs (also including two newer long-acting injectable GLP-1 RAs, such as dulaglutide and…”
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
Metadata
- Authors
- Gluud, L. L., Knop, F. K., & Vilsbøll, T.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Gluud, Lise L
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2014-12
- Volume
- 4
- Issue
- 12
- Pages
- e005325
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC4275683
- OpenAlex
- W2138748324
- Cited by
- 59
- References
- 40
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 6 · 2021: 9 · 2020: 10 · 2019: 7 · 2018: 6 · 2017: 2 · 2016: 6 · 2015: 3
- FWCI
- 0.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Sanofi
- Novo Nordisk Fonden (NNF12OC1015904)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- lixisenatide, type 2 diabetes, liver transaminases, alanine aminotransferase, aspartate aminotransferase, GLP-1 receptor agonists, obesity, overweight, liver function tests, liraglutide, exenatide, sitagliptin
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Alanine Transaminase, Aspartate Aminotransferases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Peptides, Regression Analysis, Biomarkers, Randomized Controlled Trials as Topic, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.